Everest Medicines’ Xerava (eravacycline) Receives NMPA’s Approval for Complicated Intra-Abdominal Infections in Adult Patients
- The NMPA has approved the NDA for Xerava to treat adult patients with cIAI. Xerava will be commercially available in China in Q3’23
- Under a license agreement with Tetraphase (a wholly owned subsidiary of Innoviva), Everest Medicines obtains an exclusive right to develop & commercialize Xerava in Greater China, South Korea & markets of South East Asia
- Xerava was approved for complicated cIAI in the US, EU, UK, Singapore & Hong Kong and is currently under regulatory review for cIAI in the Taiwan region. The company plan to file NDA for Taniborbactam in China in 2023 for complicated urinary tract infection & will also initiate a P-III study of EVER206, a novel polymyxin derivative in Q2’23
Ref: PRNewswire | Image: Everest medicines
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.